Rhone-Poulenc HPA-23
Executive Summary
Company recently received IND approval from FDA to begin limited clinical trials with the antiviral agent in patients with AIDS. American patients who have been receiving HPA-23 on a regular basis in France under circumstances not under control of Rhone-Poulenc will be allowed to be treated under the care of independent investigators at a limited number of U.S. medical centers.